Table 8b.
Infants (12 weeks–11 months) | Toddlers (12–35 months) | Children (3–9 years) | Adolescents (10–17 years) | Adults (18–64 years) | The elderly (≥ 65 years) | |
---|---|---|---|---|---|---|
Regulatory maximum level exposure assessment scenario considering the extension of use in FC 05.2 only | ||||||
• Mean | 25–113 | 45–113 | 39–82 | 16–40 | 12–27 | 12–24 |
• 95th percentile | 53–196 | 73–145 | 61–148 | 29–84 | 22–58 | 21–48 |
Refined estimated exposure assessment scenario considering extension of use in FC 05.2 | ||||||
Brand‐loyal scenario | ||||||
• Mean | 12.0–35.0 | 10.1–27.2 | 5.9–25.6 | 2.4–16.6 | 4.4–10.6 | 4.7–9.9 |
• 95th percentile | 27.4–65.7 | 20.6–53.6 | 11.4–55.9 | 5.1–37.0 | 9.1–25.2 | 9.4–20.2 |
Non‐brand‐loyal scenario | ||||||
• Mean | 10.2–15.8 | 5.5–11.1 | 3.7–9.9 | 1.4–6.8 | 1.8–3.7 | 1.7–3.2 |
• 95th percentile | 21.5–38.9 | 12.6–21.2 | 7.3–26.5 | 3.0–17.1 | 3.6–8.2 | 3.1–7.1 |
bw: body weight.